We’re dedicated to discover innovative drugs for patients
Our first discovery in autoimmunity, CS12192, is currently undergoing clinical trials for different autoimmune disorders. CS12192 is a JAK3/JAK1/TBK1 selective kinase inhibitor with a novel mechanism, and differs markedly from other existing clinical drugs both in target selection and molecular mechanism.
Chipscreen Biosciences focuses on cancer therapies. Chidamide ( Tusidinostat, Epidaza ® ), the first original innovative drug discovered and developed by Chipscreen, was the first oral subtype-selective histone deacetylase (HDAC) inhibitor with a novel epigenetic modulating mechanism.
Chiauranib was discovered in 2007 by Chipscreen and is now in a clinical trial in the US for the treatment of small cell lung cancer.
Chiglitazar (carfloglitazar. BilessGlu ® ), our first product targeting metabolic disorders, is a configuration-restricted pan-PPAR agonist with a chemical structure completely different from thiazolidinedione compounds.
Copyright © 2024 Chipscreen Biosciences (United States) Ltd - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.